1632125-79-1

Insulin-degrading enzyme (IDE) is a thiol-sensitive zinc-metallopeptidase that acts as the major insulin-degrading protease in vivo, mediating the termination of insulin signaling. In addition to regulating insulin action in diabetes pathogenesis, IDE plays a role in Varicella-Zoster virus infection and degradation of amyloid-β, a peptide implicated in Alzheimer’s disease. ML-345 is a small molecule inhibitor that selectively targets cysteine⁸¹⁹ in IDE with an EC₅₀ value of 188 nM. It demonstrates 10-fold selectivity for IDE over a panel of enzymes with reactive cysteine residues.

ML345 is a small molecule inhibitor of the insulin-degrading enzyme (IDE).

[1] JUAN PABLO MAIANTI. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones[J]. Nature, 2014, 511 7507: 94-98. DOI: 10.1038/nature13297
[2] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.